MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2012

Mar 5, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SYNTA PHARMACEUTICALS CORP (SNTA)
CIK: 0001157601
Period of Report: 2012-03-01

Reporting Person: Vukovic Vojo (SVP, Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-03-01	Common Stock	S	2555	$4.699	Disposed	22249	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2011, and were made in part to fund certain out-of-pocket tax withholding liabilities associated with the vesting of restricted stock granted on March 1, 2011.

F2: The shares were sold in multiple transactions at prices ranging from $4.6375 to $4.7523 per share. The price reported above is the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.